CAS 66357-59-3|CAS 71130-06-8|Azantac|Ranitidine Hydrochloride|AH 19065|[(E)-1-({2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}amino)-2-nitroethenyl](methyl)amine hydrochloride|Zant...

General Information

Structure

Molecular Formula

C₁₃H₂₃ClN₄O₃S

Molecular Mass

350.86472

Exact Mass

350.1179393

Charge

InChI

InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H/b13-9+;

InChIKey

GGWBHVILAJZWKJ-KJEVSKRMSA-N

Canonic Smiles

CN/C(=C\[N+](=O)[O-])/NCCSCc1ccc(o1)CN(C)C.Cl

Isomeric Smiles

N(Cc1ccc(o1)CSCCN/C(=C/[N+](=O)[O-])/NC)(C)C.Cl

Calculated Properties

JChem

H Acceptors

H Donor

LogD (pH = 5.5)

-1.5527394

LogD (pH = 7.4)

0.21904218

Log P

0.98147845

Molar Refractivity

95.153

Polarizability

32.323387

Polar Surface Area

86.26

Rotatable Bonds

Lipinski's Rule of Five

true

Data Source

Names and Identifiers

Synonyms

AzantacRanitidine HydrochlorideAH 19065ZantacRanitidine hydrochlorideTerposenUltidineZantidonRanibenMelfaxRanapsTauralRantecRanidilSostrilRaniplexZaedocTriggerZintacN-[2-[[[-5-[(Dimethylamino)methyl)]-2-furanyl]methyl]thio]ethyl]-N’-methyl-2-nitro-1,1-ethenediamine Hydrochloride

IUPAC name

[(E)-1-({2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}amino)-2-nitroethenyl](methyl)amine hydrochloride dimethyl[(5-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}furan-2-yl)methyl]amine hydrochloride {2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}[(E)-1-(methylamino)-2-nitroethenyl]amine hydrochloride

IUPAC Traditional name

Names and Identifiers

Registration numbers

PubChem SID

PubChem CID

CAS Number

EC Number

MDL Number

Registration numbers

Properties

Safety Information

Storage Condition

-20°C

Hygroscopic, -20°C Freezer, Under Inert Atmosphere

RTECS

KM6557000

German water hazard class

MSDS Link

Download link

Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

Pharmacology Properties

Gene Information

human ... HRH2(3274)

Mechanism of Action

Histamine H 2-receptor antagonist

Properties

Related Proteins

No Data Available

Click here to submit data

Molecular Spectra

No Data Available

Click here to submit data

Molecule Details

Selleck Chemicals

S1801

Research Area: Metabolic Disease
Biological Activity:
Ranitidine (Zantac) is a histamine H2-receptor antagonist with IC50 of 3.3 ± 1.4 µM. It inhibits stomach acid production. It is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives. It has 10% the affinity that cimetidine has to CYP450 so it causes fewer side effects, but other H2 blockers famotidine and nizatidine have no CYP450 significant interactions. [1][2]

Sigma Aldrich

R101

Biochem/physiol Actions
H2 histamine receptor antagonist; anti-ulcer agent.

44404

Biochem/physiol Actions
H2 histamine receptor antagonist; anti-ulcer agent.

TRC

R120000

A histamine H2-receptor antagonist which inhibits gastric acid secretion. Antiulcerative.

Molecule Details

References

PubChem Literature

From Data Sources

• Herling AW et al. Agents Actions. 1987 Feb;20(1-2)

• Hohnjec, M., et al.: Anal. Profiles Drug Subs., 15, 533 (1979)

• Bradshaw, J., et al.: Brit. J. Pharmacol., 66, 464 (1979)

• Berstad, A., et al.: Scand. J. Gastroenterol, 15, 637 (1979)

• Riley, A.J. et al., Curr. Clin. Pract. Ser., (Eds.), No. 1: Ranitidine, Excerpta Medica, Amsterdam, 1982, (book)

• Brogden, R.N. et al., Drugs, 1982, 24, 267, (rev, pharmacol)

• Hohnjec, M. et al., Anal. Profiles Drug Subst., 1986, 15, 533, (rev, synth, anal, metab)

• Spurling, N.W. et al., Hum. Toxicol., 1989, 8, 23, (chronic tox)

• Gaginella, T.S. et al., Drug Intell. Clin. Pharm., 1983, 17, 873, (rev, pharmacol)

• Daly, M.J. et al., Br. J. Pharmacol., 1981, 72, 49; 55, (pharmacol)

• Kojic-Prodic, B. et al., Acta Cryst. B, 1982, 38, 1837, (cryst struct)

• Wormsley, K.G., Drugs, 1993, 46, 976, (tox, rev)

• Geraldes, C.F. et al., Magn. Reson. Chem., 1987, 25, 203, (pmr, cmr)

• Misiewicz, J.J. et al., Curr. Clin. Pract. Ser., 1984, 15, (book)

• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 2946

• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, RBF400

• The Landmark Papers: The H2-Receptor Antagonists, (Ed. Pounder, R.E.), Science Press, 1990, (pharmacol, book)

• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 1209; 1211

• Ger. Pat., 1978, Allen and Hanburys, 2 734 070; CA, 88, 190580b, (synth, pharmacol)

• Daly, M.J. et al., Prog. Med. Chem., 1983, 20, 337, (rev, pharmacol)

• Cholerton, T.J. et al., J.C.S. Perkin 2, 1984, 1761, (uv, ir, pmr, struct)

• Kirch, W., Pharmacol. Ther., 1987, 33, 129, (rev)

• Grant, S.M. et al., Drugs, 1989, 37, 801, (pharmacol, rev)

• Bradshaw, J., Chron. Drug Discovery, 1993, 3, 45, (rev)

References

Bioactivity

PubChem BioAssay

Bioactivity